OXFORD INDUSTRIES INC

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

Oxford Square Capital Corp. Q2 2026 Earnings Call Summary

Moby summary of Oxford Square Capital Corp.'s Q2 2026 earnings call

New Oxford man accused of jumping out front window to shoot visitor

Entergy signs with Hyundai Steel-Posco as part of recent metals deals

In other news, Alcoa plans to invest $65 million to expand and upgrade its Norway smelter for recycled content, and FabArc Steel Supply broke ground on its Oxford, Alabama, headquarters.